| +0.03 / +0.15%|
The 4 analysts offering 12-month price forecasts for Trinity Biotech PLC have a median target of 33.00, with a high estimate of 37.00 and a low estimate of 30.00. The median estimate represents a +60.19% increase from the last price of 20.60.
The current consensus among 5 polled investment analysts is to Buy stock in Trinity Biotech PLC. This rating has held steady since August, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.